IRONWOOD PHARMACEUTICALS,INC. (NASDAQ:IRWD) Files An 8-K Results of Operations and Financial Condition

IRONWOOD PHARMACEUTICALS,INC. (NASDAQ:IRWD) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item2.02 Results of Operations and Financial Condition.

On May8, 2017,Ironwood Pharmaceuticals,Inc. issued a press
release containing an update on its recent business activities as
well as those for the quarter ended March31, 2017. A copy of the
press release is furnished as Exhibit99.1 and is incorporated
herein by reference.

The press release is being furnished to Item 2.02 of this Current
Report on Form8-K and shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
Section, nor shall such document be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act except as shall be expressly set
forth by specific reference in such filing.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.

Description

99.1

Ironwood Pharmaceuticals,Inc. Press Release dated May8,
2017


About IRONWOOD PHARMACEUTICALS, INC. (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

IRONWOOD PHARMACEUTICALS, INC. (NASDAQ:IRWD) Recent Trading Information

IRONWOOD PHARMACEUTICALS, INC. (NASDAQ:IRWD) closed its last trading session up +0.08 at 16.10 with 753,628 shares trading hands.

An ad to help with our costs